66 related articles for article (PubMed ID: 12009006)
41. Cloning and characterization of osteoclast precursors from the RAW264.7 cell line.
Cuetara BL; Crotti TN; O'Donoghue AJ; McHugh KP
In Vitro Cell Dev Biol Anim; 2006; 42(7):182-8. PubMed ID: 16948499
[TBL] [Abstract][Full Text] [Related]
42. Absence of platelet-activating factor receptor protects mice from osteoporosis following ovariectomy.
Hikiji H; Ishii S; Shindou H; Takato T; Shimizu T
J Clin Invest; 2004 Jul; 114(1):85-93. PubMed ID: 15232615
[TBL] [Abstract][Full Text] [Related]
43. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
[TBL] [Abstract][Full Text] [Related]
44. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
[TBL] [Abstract][Full Text] [Related]
45. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
46. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
47. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
Xiao XH; Zhou HD; Yuan LQ; Xie H; Liao EY
Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(24):2102-6. PubMed ID: 15730627
[TBL] [Abstract][Full Text] [Related]
48. c-myc is required for osteoclast differentiation.
Battaglino R; Kim D; Fu J; Vaage B; Fu XY; Stashenko P
J Bone Miner Res; 2002 May; 17(5):763-73. PubMed ID: 12009006
[TBL] [Abstract][Full Text] [Related]
49. [Transcription factors in osteoclast differentiation].
Matsuo K; Irie N
Nihon Rinsho; 2005 Sep; 63(9):1541-6. PubMed ID: 16164209
[TBL] [Abstract][Full Text] [Related]
50. [Suppressive effects for osteoclastogenesis regulated by RANKL signal].
Miyauchi Y; Miyamoto T
Clin Calcium; 2011 Aug; 21(8):1141-7. PubMed ID: 21814018
[TBL] [Abstract][Full Text] [Related]
51. RANKL-independent modulation of osteoclastogenesis.
Feng W; Guo J; Li M
J Oral Biosci; 2019 Mar; 61(1):16-21. PubMed ID: 30929797
[TBL] [Abstract][Full Text] [Related]
52. The interplay between Mad and Myc in proliferation and differentiation.
Zhou ZQ; Hurlin PJ
Trends Cell Biol; 2001 Nov; 11(11):S10-4. PubMed ID: 11684436
[TBL] [Abstract][Full Text] [Related]
53. Regulated expression and function of the c-Myc antagonist, Mad1, during a molecular switch from proliferation to differentiation.
Cultraro CM; Bino T; Segal S
Curr Top Microbiol Immunol; 1997; 224():149-58. PubMed ID: 9308238
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
